Alzamend Neuro eliminates Series A convertible preferred stock via Certificate of Elimination

Alzamend Neuro, Inc.

Filed Certificate of Elimination with Delaware Secretary of State on July 9, 2025 to cancel Series A Preferred Stock.
Certificate of Elimination removes all designations for Series A Preferred Stock from the company's charter.
No changes to fiscal year were made despite Item 5.03 title; only preferred stock elimination occurred.

item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.